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Abstract		
Glutamine	is	a	non-essential	amino	acid	mostly	synthetized	and	released	to	the	blood	
stream	by	the	skeletal	muscle	and	the	lungs.	The	enterocytes	and	the	immune	system	
cells	are	great	glutamine	consumers	and	glutamine	is	crucial	for	their	correct	function.	
Due	to	metabolic	changes	occurred	during	critical	illness,	the	plasma	level	of	glutamine	
becomes	low	and	skeletal	muscle	becomes	depleted.	Treatment	with	glutamine	tries	to	
normalize	plasma	levels	and	improve	the	immune	cell	response.	Glutamine’s	chemical	
properties	are	unfavorable	for	their	storage	and	so	new	ways	of	glutamine	delivery	are	
enveloped.	 The	 most	 current	 used	 alternative	 source	 are	 glutamine	 dipeptides.	
Administration	of	glutamine	can	be	supplying	the	artificial	nutrition	support	or	being	
administrated	 independently;	 by	 parenteral	 or	 by	 enteral	 route.	 Traditional	 trials	 of	
glutamine	 supplementation	 demonstrate	 favorable	 results	 in	 patients	 with	 critical	
illness.	However,	newer	trials	which	included	more	study	population,	among	which	the	
REDOX	 trial,	 where	 not	 able	 to	 confirm	 these	 results.	 A	 trend	 towards	 favorable	
outcomes	were	found	in	surgical	and	oncological	patients	with	intravenous	glutamine	
supplementation	 on	 physiological	 doses	 without	 renal	 and/or	 liver	 dysfunction.	 In	
contrast,	there	was	also	found	high	glutamine	baseline	levels	in	a	subgroup	of	critically	
ill	 patients.	With	 all	 the	 available	 clinical	 research	 information,	 it	 is	 still	 not	 clear	 if	
glutamine	should	be	included	in	the	routine	clinical	use.		
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Resumen	
La	 glutamina	 es	 un	 aminoácido	 no	 esencial	 sintetizado	 y	 liberado	 a	 la	 circulación	
sanguínea	 mayoritariamente	 por	 la	 musculatura	 esquelética	 y	 los	 pulmones.	 Los	
enterocitos	 y	 las	 células	 del	 sistema	 inmunitario	 son	 grandes	metabolizadores	 de	 la	
glutamina	 y	 ésta	 es	 crucial	 para	 su	 funcionamiento	 óptimo.	 Debido	 a	 cambios	
metabólicos	 sufridos	 en	 el	 paciente	 crítico,	 los	 niveles	 sanguíneos	 de	 glutamina	
disminuyen	 significativamente	 y	 se	 observa	 una	 depleción	 de	 glutamina	 en	 la	
musculatura	esquelética.	El	tratamiento	con	glutamina	tiene	como	objetivo	normalizar	
los	niveles	plasmáticos	y	mejorar	la	respuesta	del	sistema	inmunitario.	Las	propiedades	
químicas	 de	 la	 glutamina	 son	 desfavorables	 para	 su	 almacenaje	 y	 por	 eso	 se	 han	
desarrollado	 nuevas	 estructuras	 químicas	 de	 glutamina	 para	 ser	 administradas.	 La	
fuente	 alternativa	 más	 utilizada	 actualmente	 son	 los	 dipéptidos	 de	 glutamina.	 La	
administración	de	glutamina	se	puede	realizar	suplementando	a	la	nutrición	artificial	o	
administrándose	de	forma	independiente;	por	vía	parenteral	o	bien	por	vía	enteral.	Los	
estudios	tradicionales	sobre	 la	suplementación	con	glutamina	demuestran	resultados	
favorables	en	el	paciente	crítico.	En	cambio,	estudios	posteriores	que	incluyen	un	mayor	
número	de	pacientes,	entre	los	cuales	destaca	el	estudio	REDOX,	no	han	sido	capaces	
de	confirmar	dichos	resultados.	Los	estudios	demuestran	una	tendencia	favorable	en	
pacientes	quirúrgicos	y	oncológicos	con	suplementación	de	glutamina	por	vía	parenteral	
en	dosis	 fisiológicas	que	no	presentaban	 insuficiencia	 renal	y/o	hepática.	En	cambio,	
también	se	han	detectado	en	un	subgrupo	de	pacientes	niveles	elevados	de	glutamina.	
Aun	 así,	 con	 toda	 la	 información	 clínica	 disponible	 actualmente,	 sigue	 siendo	 poco	
concluyente	la	inclusión	de	la	glutamina	en	la	práctica	clínica	habitual.		 	
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Integrating	educational	fields	
Clinical	pharmacy	is	one	of	the	pharmacy	specialties	where	pharmacists	take	care	of	the	
correct	 and	 safe	 utilization	 of	 drugs	 and	 other	 medical	 substances	 through	
pharmaceutical	 care	 and	 intervention;	 inform	 and	 advise	 patients	 about	 their	
treatment,	support	physicians	and	other	healthcare	professionals	by	 informing	about	
the	 rational	 use	 of	 medication,	 conduct	 observational	 studies	 and	 clinical	 trials	 of	
therapeutic	 effects	 and	 educate	 civilization	 to	 promote	 health	 and	 prevent	 disease.	
These	are	just	some	of	the	clinical	pharmacist	responsibilities.		
Hospital	pharmacy,	a	branch	of	clinical	pharmacy,	has	further	specific	functions	in	the	
hospital	 ambit	 taking	 charge	 of	 hospital	 treated	 diseases,	 drugs	 for	 hospital	 use	 or	
hospital	diagnostic,	toxicology	and	pharmacokinetics	and	elaboration	of	parenteral	and	
enteral	nutrition.	Prescribing	and	preparing	parenteral	nutrition	individualized	for	every	
patient,	including	glutamine	supplementation,	is	part	of	their	daily	practices.	Therefore,	
the	 main	 education	 field	 of	 this	 final	 degree	 project	 is	 clinical	 pharmacy	 and	
pharmacotherapy.		
In	order	to	understand	the	implications	of	glutamine	supplementation	in	the	critically	ill	
patients,	physiology	and	physiopathology	is	the	second	education	field	integrated	in	this	
literature	review.	Glutamine	physiological	functions,	the	patients’	metabolic	adaptation	
response	to	critical	illness	and	glutamine	requirements	and	utilization	during	a	stressful	
situation	are	some	of	the	studied	and	mentioned	contents	of	this	field.	
Finally,	pharmaceutical	technology	is	integrated	as	part	of	the	clinical	hospital	pharmacy	
activities	in	elaboration	of	glutamine	solutions	and	glutamine-supplemented	parenteral	
nutrition.	This	part	has	some	particular	 interest	as	glutamine	has	chemical	properties	
which	make	the	routine	clinical	use	difficult	and	could	have	an	impact	on	the	treatment	
effects.		
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Introduction	
In	the	last	years,	the	importance	of	nutrition	support	has	been	raised.	The	prevalence	of	
hospital	 malnutrition	 was	 a	 common	 finding	 and	 appears	 to	 be	 an	 independent	
predictor	of	outcomes	and	associated	with	a	higher	 rate	of	morbidity	and	mortality.	
Nutrient	deficiency	is	one	of	the	most	common	causes	of	immunodeficiency	as	nutrition	
is	a	critical	determinant	of	the	immune	system	response.	Therefore,	physicians	start	to	
consider	adequate	nutrition	support	crucial	for	recovery1.	
Critically	 ill	 patients	 are	mostly	 not	 able	 to	 eat	 (enough)	 by	 themselves,	 so	 artificial	
nutrition	support,	defined	as	the	administration	of	nutrient	solutions	by	the	enteral	or	
intravenous	(parenteral)	routes,	is	required	to	supply	all	or	the	remainder	part	of	the	
patients’	 needs.	 Enteral	 nutrition	 support	 is	 preferred.	 Parenteral	 nutrition	 is	 only	
indicated	when	enteral	route	is	contraindicated	(e.g.	in	case	of	gastric	complications)	or	
fails	to	cover	the	patients’	requirements1.	
Until	 now,	 controversy	 persists	 in	 defining	 adequate	 nutrition	 support.	 Guidelines	
between	 hospital	 settings	 vary	 in	 timing,	 caloric	 quantity,	 protein	 needs,	
monetarization,	 use	 of	 adjuvant	 therapies	 such	 as	 probiotics	 or	 immunonutrition,	
support	during	specific	conditions,	etc.	Many	clinical	 trials	are	performed	 in	order	 to	
clarify	 findings	 and	 to	 develop	 recommendations	 for	 adequate	 nutrition	 support	
practice,	including	for	particular	nutrients,	such	as	glutamine.				
Glutamine	 is	 the	most	abundant	 free	amino	acid	 found	 in	 the	human	body	pool	and	
blood	stream.	In	a	healthy	man,	the	plasma	values	range	between	450	and	650	µmol/L	
although	 intracellular	 levels	are	25-30	 times	greater.	Glutamine	 is	 considered	a	non-
essential	 amino	 acid;	 it	 is	 not	 a	 required	 dietary	 nutrient	 for	 humans	 as	 it	 can	 be	
synthesized	endogenously2.		
The	physiological	pathway	and	metabolism	of	glutamine	have	been	studied	during	years	
and	glutamine	has	showed	to	be	an	important	substrate	for	different	tissues,	especially	
for	the	gut	and	the	immune	system3,4.	When	the	immune	system	is	activated	(e.g.	during	
illness)	 different	 human	 defense	 systems	 increase	 their	 glutamine	 consumption	 and	
overcome	the	endogenous	synthesis	capacity,	causing	glutamine	muscle	depletion	and	
low	 plasma	 levels.	 Glutamine	 becomes	 essential	 and	 therefore	 it’s	 considered	 a	
conditionally	essential	amino	acid2.	
In	order	to	cover	the	metabolic	deficiency	and	to	let	critically	ill	patients	benefit	from	
different	 glutamine	 functions,	 randomized	 clinical	 trials	 have	 been	 performed	 with	
glutamine	supplementation.	Most	of	the	earlier	small	trials	using	parenteral	glutamine	
supplementation	 could	 prove	 the	 glutamine	 efficacy	 by	 enhancement	 of	 clinical	
outcomes	in	critically	ill	patients.	
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Over	time,	the	field	of	nutrition	support	progressed	from	simply	solving	the	problem	of	
providing	enough	micronutrients	to	meet	metabolic	demands	to	the	current	search	for	
individual	 nutrient	 regimes	 to	 optimize	 immune	 function	 and	 cell	 recovery.	 Those	
nutrients	which	 stimulate	 the	 cellular	 defense	 system	 and	 reduce	 infection	 or	 other	
complications	in	pharmacologic	doses,	like	glutamine,	are	called	“pharmaconutrients”	
or	“immunonutrients”5.	
Nevertheless,	when	this	new	concept	was	putted	in	practice	by	a	scientific	strong	multi-
center	randomized	clinical	trial,	known	as	the	Reducing	Death	due	to	Oxidative	Stress	
(REDOX)	 trial6,	 the	results	were	not	as	expected.	This	 trial	 fails	 in	 finding	any	benefit	
from	 glutamine	 supplementation	 and	 could	 even	 associate	 an	 increased	 28-day	
mortality	to	the	intervention	group.	This	study	raised	new	questions	around	the	actual	
evidence	of	glutamine	support	in	critical	illness.	
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Objectives	
The	 aim	 and	 principal	 objective	 of	 this	 literature	 review	was	 to	 discuss	 the	 current	
clinical	evidence	related	to	parenteral	glutamine	supplementation	in	the	intensive	care	
unit	(ICU)	since	the	results	of	the	REDOX	trial	have	opened	a	new	discussion	around	this	
subject.	
Secondary	study	objectives	were:	
• To	learn	about	the	metabolic	pathways	and	physiological	functions	of	glutamine	
in	a	healthy	human	body.	
• To	 figure	 out	 the	 potential	 beneficial	 implications	 of	 glutamine	 in	 critically	 ill	
patients.	
• To	understand	the	process	of	glutamine	supplementation	in	the	routine	clinical	
practice,	 from	 preparation	 to	 administration,	 and	 the	 different	 associated	
problems.	
• To	 have	 knowledge	 of	 the	 current	 clinical	 guidelines	 recommendations	 of	
glutamine	supplementation	in	the	critically	ill	patients.		
• To	analyze	the	existing	scientific	evidence	of	glutamine	supplementation	during	
the	years	and	interpret	their	results	according	to	different	identified	variables.		
• To	interpret	the	results	of	the	REDOX	trial	and	to	know	why	these	differ	from	the	
earlier	realized	studies.	
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Material	and	methods	
This	original	literature	review	about	intravenous	glutamine	supplementation	in	the	ICU	
was	 performed	 between	 February	 and	May	 2017.	 PubMed,	 a	 free	 research	website	
connected	 to	 the	Medical	 Literature	Analysis	and	Retrieval	 System	online	 (MEDLINE)	
database,	which	contains	the	most	relevant	publications	in	the	setting	of	life	science	and	
biomedics,	 was	 used	 to	 explore	 and	 acquire	 scientific	 articles	 of	 interest.	 The	
bibliographic	review	was	completed	in	English.	Only	free	and	facilitated	by	the	Centre	
de	Recursos	per	a	l’Aprenentatge	i	la	Investigació	(CRAI)	articles	could	be	consulted	and	
included.	The	REDOX	trial,	which	promotes	to	produce	the	actual	review,	was	provided	
by	my	mentor	of	this	final	degree	project.		
First,	 an	exhaustive	bibliographic	 search	of	background	 information	about	 glutamine	
and	critical	illness	was	carried	out	to	understand	and	interpret	the	results	of	the	later	
included	 clinical	 trials.	 Some	 of	 the	 main	 keywords	 utilized	 in	 this	 research	 were	
“glutamine”	 in	 combination	 with	 “physiology”,	 “functions”,	 “critical	 illness”,	
“metabolism”,	“preparation”	and	“kinetics”.	From	these	first	found	articles,	new	sources	
of	interest	were	provided	from	its	bibliography.		
Second,	 the	 most	 relevant	 current	 guidelines	 of	 glutamine	 supplementation	 were	
extracted	from	the	official	websites	of	the	American	Society	for	Parenteral	and	Enteral	
Nutrition	(ASPEN),	The	European	Society	for	Clinical	Nutrition	and	Metabolism	(ESPEN)	
and	the	Critical	Care	Nutrition	at	the	Clinical	Evaluation	Research	Unit	(CERU).	
Third,	clinical	trials	and	meta-analysis	were	obtained	using	the	search	terms	“glutamine”	
in	 combination	 of	 “parenteral”,	 “supplementation”,	 “administration”,	 “nutrition”,	
“support”,	“intravenous”,	“critically	ill	patients”,	“critical	illness”	and	“ICU”,	applying	the	
search	filters	“clinical	trial”	and	“meta-analysis”.	More	clinical	trials	were	extracted	from	
these	 consulted	meta-analysis.	Clinical	 trials	 and	meta-analysis	were	 included	 if	 they	
focused	mostly	on	parenteral	glutamine	support	and	on	patients	of	the	intensive	care	
unit.	These	studies	were	classified	in	if	they	were	performed	before	the	REDOX	trial	(pre-
REDOX)	or	after	the	REDOX	trial	(post-REDOX).		
Finally,	 commentaries	 on	 the	 REDOX	 trial	 and	 other	 recent	 literature	 reviews	 of	
glutamine	 supplementation	 in	 critically	 ill	 patients	were	explored	 and	 interpreted	 as	
inspiration	for	my	own	point	of	view.			
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Results	and	discussion	1	Glutamine	1.	1	Endogen	synthesis	
In	 physiological	 conditions,	 dietary	 glutamine	 coming	 from	 different	 protein	 sources	
only	represents	12%	of	the	whole-body	glutamine	appearance	so	glutamine	availability	
depends	more	on	the	endogen	synthesis7.		
The	glutamine	synthetase	is	responsible	for	the	endogenous	formation	of	glutamine	by	
catalyzing	 the	 condensing	 reaction	of	 glutamate	and	ammonia	 (NH4+)	 in	presence	of	
adenosine	 triphosphate	 (ATP).	 This	 cytosolic	 enzyme	 is	mostly	 found	 in	 the	 skeletal	
muscle	and	lungs2.	𝐺𝑙𝑢𝑡𝑎𝑚𝑎𝑡𝑒 + 𝐴𝑇𝑃 + 𝑁𝐻./ → 𝐺𝑙𝑢𝑡𝑎𝑚𝑖𝑛𝑒 + 𝐴𝐷𝑃 + 𝑃𝑖	
On	the	other	hand,	glutamine	is	hydrolyzed	by	the	mitochondrial	glutaminase	obtaining	
glutamate	 and	 ammonia.	 Rapidly	 dividing	 cells,	 like	 enterocytes	 and	 some	 immune	
system	cells,	present	a	high	activity	of	this	enzyme	and	are	consequently	great	glutamine	
consumers2.	 𝐺𝑙𝑢𝑡𝑎𝑚𝑖𝑛𝑒 + 𝐻4𝑂 → 𝐺𝑙𝑢𝑡𝑎𝑚𝑎𝑡𝑒 + 𝑁𝐻./	
The	metabolism	of	glutamine	depends	on	the	presence	and	activity	of	both	enzymes.	
Both	are	dispersed	differently	along	the	human	body	and	so	glutamine	production	and	
consumption	 differs	 between	 tissues.	 In	 physiological	 conditions,	 there	 is	 a	 balance	
between	 both	 reactions	 and	 the	 homeostasis	 of	 glutamine	 is	maintained.	 However,	
some	 psychopathological	 conditions	 can	 lead	 to	 a	 shortage	 of	 glutamine	 with	
consequently	harmful	effects	on	high-consume	tissues2,7.		1.2	Metabolic	pathways	
Glutamine	 acts	 as	 nitrogen	 and	 carbon	 skeletal	 source	 in	 order	 to	maintain	 the	 cell	
function.	 Glutamine	 and	 glutamate	 are	 important	 substrates	 in	 the	 intermediary	
metabolism	of	the	cells	and	are	precursors	of	many	compounds	(Figure	1)3,7.	
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Figure	 1.	 Overview	 of	 glutamine	 and	 glutamate	 metabolism.	 Glutamate	 is	 produced	 from	
glutamine	 through	glutaminase	activity.	Glutamate	can	be	converted	 into	glutamine	 through	
glutamine	 synthesase	 activity.	 TCA:	 tricarboxylic	 acid.	 GABA:	 gamma-aminobutyric	 acid.	
[Adapted	Biolo	et	al.7].	
Glutamine	metabolism	occurs	in	all	tissues	and	cells	although	some	metabolic	pathways	
preferentially	occur	in	some	specific	organs.	Glutamine	use	for	gluconeogenesis	occurs	
typically	 in	 kidneys	 and	 liver	 whereas	 gamma-aminobutyric	 acid	 (GABA)	 synthesis	 is	
more	observed	in	neurons.			
Furthermore,	glutamine	is	used	as	energy	source	by	the	rapidly	dividing	cells,	mostly	of	
the	immune	system,	and	enterocytes.		1.3	Physiological	functions	
As	 the	 implied	 enzymes	 in	 the	 metabolism	 of	 glutamine	 and	 the	 related	 metabolic	
pathways	 vary	 hardly	 between	 tissues,	 glutamine	 has	 not	 the	 same	 importance	 to	
maintain	 their	 correct	 cell	 function.	 Some	 tissues	 consume	 large	 quantities	 and	
glutamine	is	an	essential	metabolic	precursor.	These	tissues	are	the	most	affected	when	
shortage	of	glutamine	occurs.	
Lungs	and	skeletal	muscle	are	the	most	important	storages	of	glutamine	of	the	human	
body.	Both	release	big	quantities	of	glutamine	to	plasma	and	are	an	important	source	
of	glutamine	in	physiological,	postabsorptive	and	hypercatabolic	states,	characterized	in	
metabolic	 stress	 states.	 This	 is	 possible	 due	 to	 the	 high	 glutamine	 synthesis	 activity	
present	in	both	organs.	
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Glutamine	represents	more	than	50	per	cent	of	the	intracellular	free	amino	acid	pool	of	
the	skeletal	muscle	and	is	a	normal	constituent	of	many	muscle	proteins.	Physiological	
intracellular	glutamine	levels	are	significantly	higher	than	extracellular	levels.	Glutamine	
is	obtained	from	in	novo	synthesis	and,	in	less	proportion,	by	proteolysis.	A	large	amount	
of	glutamine	is	released	to	plasma	and	a	small	part	is	used	by	the	own	muscle	tissue,	
mostly	for	protein	synthesis7.	
In	the	liver,	bidirectional	flux	of	glutamine	exists	as	both	synthesis	and	hydrolysis	occurs.	
The	 net	 flux	 depends	 on	 the	 body	 needs	 and	 state	 at	 each	 moment,	 as	 glutamine	
metabolism	 adapts	 itself	 and	 regulates	 glutamine	 homeostasis.	 The	 perivenous	
scavenger	cells	of	the	liver	are	responsible	for	the	synthesis	of	glutamine,	cleaning	up	
the	bloodstream	from	ammonia.	In	the	periportal	cells,	glutamine	is	broken	up	and	used	
especially	for	gluconeogenesis	and	urea	synthesis3.	
On	the	other	hand,	gut	and	immune	system	are	the	biggest	consumers	of	glutamine,	
making	 glutamine	 an	 especially	 important	 factor	 for	 the	 correct	 cell	 function.	 Gut	
obtains	 glutamine	 mostly	 from	 the	 lumen	 in	 postpandrial	 state	 and	 from	 the	
bloodstream	in	postabsorptive	state	and	is	required	in	order	to	conserve	the	integrity,	
function	and	metabolism	of	the	gut,	used	as	major	fuel	by	the	enterocytes2,3.	As	a	result,	
glutamine	helps	reducing	the	bacterial	 translocation	and	supports	the	 immunological	
function	 of	 the	 intestine	 tract,	 being	 beneficial	 to	 reduce	 infection	 complications	 in	
critically	ill	patients8.	
Lymphocytes	and	macrophages	are	great	glutamine-spending	immune	cells	during	their	
proliferation	processes,	which	occurs	when	the	 immune	system	is	activated	due	to	a	
need	of	protecting	against	disease	and	foreign	bodies.	In	fact,	proliferating	lymphocytes	
have	 a	 10-fold	 greater	 glutamine	 utilization	 compared	with	 resting	 cells9.	 Glutamine	
provides	 the	 immune	 system	 metabolic	 intermediates	 for	 synthesis	 of	 purines	 and	
pyrimidines	and	is	used	as	energy	source4.	
Nevertheless,	 glutamine	 has	 other	 essential	 functions	 related	 to	 cell	 survival	 during	
stress.	Glutamine	stimulates	the	expression	of	heat	shock	proteins	(HSP),	which	are	a	
group	of	proteins	which	enhance	cellular	survival	in	stressful	situations10.	Glutamine	and	
glutamate	 are	 also	 precursors	 for	 glutathione	 synthesis	 which	 play	 a	 role	 in	 the	
antioxidant	defenses	of	the	cells11.	
Kidneys	 are	 small	 consumers	 of	 glutamine,	 where	 it’s	 used	 mostly	 for	 renal	
gluconeogenesis	 and	 ammoniagenesis.	 New	 synthetized	 ammonia	 is	 excreted	 and	
linked	to	increased	acid	excretion,	helping	to	sustain	the	acid-base	balance.	In	acidosis	
conditions,	 glutamine	 renal	 absorption	becomes	higher	 satisfying	 the	higher	need	of	
ammonia	excretion3.	
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Generally,	liver	and	kidneys	are	the	principal	organs	implied	in	glutamine	metabolism.	
Therefore,	 when	 liver	 and	 renal	 functions	 are	 impaired,	 the	 level	 of	 glutamine	 and	
ammonia	in	plasma	increases	and	becomes	harmful4.		2	Critical	illness	2.1	Metabolic	changes	
Critical	 illness	 is	paired	with	an	adaptive	stress	 response.	This	 typical	and	complicate	
response	 implies	changes	 in	neuroendocrine	pathways,	 including	an	activation	of	the	
sympathetic	 nervous	 system	 and	 the	 hypothalamus-pituitary	 axis	 which	 results	 in	
increased	circulating	levels	of	stress	hormones,	such	as	corticoids	and	catecholamines.	
Besides,	 inflammation	 mediators	 and	 cytokines	 are	 produced	 in	 high	 quantities.	 All	
these	 chemical	 changes	 affect	 the	 metabolic	 state	 of	 the	 patient,	 leading	 to	 a	
generalized	catabolic	state	with	resistance	to	anabolic	signals	(such	as	insulin)12.		
Clinically,	those	patients	with	stress	induced	metabolism	have	variations	in	their	energy	
expenditure,	 use	 different	 sources	 of	 energy	 substrates,	 suffer	 from	 stress	
hyperglycemia	 (due	 to	 excessive	 gluconeogenesis	 and	 glycogenesis	 and	 insulin	
resistance),	experience	alterations	in	lactate	metabolism	and	have	an	increased	rate	of	
lipolysis	and	proteolysis	(therefore	lean	body	mass	is	loosed).	The	nitrogen	balance	of	
these	patients	is	negative,	which	reflect	the	higher	protein	breakdown	than	synthesis12.		2.2	Glutamine’s	role		
Glutamine	 plays	 a	 vital	 role	 in	 critically	 ill	 patients	 by	modulating	 the	 inflammatory	
response,	inducing	glutathione	synthesis	and	promoting	HSP	expression.	The	demands	
of	glutamine	are	therefore	increased	and	deficiency	is	especially	harmful	as	rapid	cell	
proliferation	is	required11.	
Skeletal	muscle	and	lungs	are	responsible	to	maintain	the	glutamine	plasma	levels	by	
releasing	higher	levels	of	glutamine	to	the	extracellular	medium	in	intention	to	subserve	
the	demands	of	 glutamine.	 The	 associated	metabolic	 changes	 to	 the	 adaptive	 stress	
response	affect	consequently	the	cellular	glutamine	metabolism.	The	increased	levels	
of	stress	hormones,	primarily	glucocorticoids,	can	up-regulate	the	glutamine	synthetase	
expression	and	increase	glutamine	release	to	plasma7,11.	
However,	 the	 endogenous	 glutamine	 production	 becomes	 insufficient	 and	 skeletal	
muscle	spends	glutamine	from	the	intracellular	pool	and	by	breaking	down	own	muscle	
proteins,	 promoted	 by	 the	 overall	 catabolic	 state.	 The	 human	 body	 reservoir	 of	
glutamine	becomes	depleted	as	the	increased	requirements	overcome	the	muscle	and	
lung	 releasing	 and	 glutamine	 becomes	 essential2,7.	 In	 consequent,	 blood	 glutamine	
levels	fall13.		
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Low	glutamine	plasma	and	tissue	levels	impair	the	cellular	stress	response	and	altered	
immune	function.	Glutamine	deficiency	has	been	associated	to	the	severity	of	 illness	
and	hospital	mortality	as	 independent	variables13,14.	Critically	 ill	patients	may	benefit	
from	glutamine	supplementation	in	order	to	normalize	glutamine	levels	and	promote	
several	 metabolic	 cell	 functions	 (Figure	 2)15.	 Nevertheless,	 critical	 illness	 is	 not	
necessarily	associated	with	a	low	plasma	glutamine13.	
	
Figure	2.	Potential	mechanisms	of	GLN’s	beneficial	effects	in	critically	ill	patients.	NO:	nitric	oxid.	
NF-kB:	nuclear	transcription	factor.	ATP:	adenosine	triphosphate.	[Adapted	from	Wischmeyer	
et	al.15].		
Doses	 of	 glutamine	 administration	 above	 the	 patient	 requirements	 or	 glutamine	
supplementation	 to	 those	 patients	 suffering	 from	 liver	 or	 renal	 failure	 can	 result	 in	
strongly	elevated	amino	acids	and	ammonia	levels	and	consequently	have	toxic	effects4.	3	Glutamine	preparation		
Glutamine	preparation	for	intravenous	administration	has	several	complications	due	to	
its	unfavorable	chemical	properties.	The	solubility	of	free	glutamine	is	approximately	35	
g/L	 and	 considerably	 increases	 the	 volume	 of	 fluid	 to	 infuse	 in	 order	 to	 achieve	 a	
beneficial	dose	and	avoid	precipitation.	At	the	same	time,	free	glutamine	is	decomposed	
to	potentially	toxic	pyroglutamic	acid	and	ammonia	during	storage	in	aqueous	solutions	
(Figure	3).	Even	short	periods	of	time	are	enough	to	accumulate	toxic	compounds	and	
produce	damage.	 Increased	temperatures,	as	applied	during	heat	sterilization,	 fasten	
the	breakdown	process16.	
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Figure	3.	Schematic	illustration	of	glutamine	degradation	to	pyroglutamic	acid	and	ammonia.		
In	order	to	preserve	stability,	glutamine	is	provided	as	white	and	crystalline	powder	or	
as	frozen	solution.	Dry	powder	of	l-glutamine	is	used	to	form	a	glutamine	solution,	which	
must	be	freshly	prepared	under	strict	septic	conditions	before	administration	due	to	its	
poor	stability.	Preparation	instructions	of	l-glutamine	solution	from	powder	could	be	the	
following:	
1. Determine	the	amount	of	glutamine	and	water	for	injection	needed,	taking	into	
account	the	solubility	of	glutamine	(the	concentration	of	glutamine	should	not	
exceed	2.5%),	the	amount	of	glutamine	required	to	produce	the	desired	effect	
and	the	volume	of	solution	able	to	be	administrated	to	the	patient.	
2. User	water	on	room	temperature	and	do	not	heat	to	stimulate	solubility,	as	this	
speed	up	the	degradation	of	glutamine.		
3. Add	water	to	a	clean	and	dry	mixing	vessel	and	add	the	powder	slowly	to	the	
water	and	mix.	Ensure	that	there	are	no	visible	particles	in	the	solution.		
4. Sterilize	 by	 filtration	 through	 a	 sterile	 0.22	µm	 filter	 into	 a	 sterile	 collection	
vessel.		
Glutamine	 solution	 can	 be	 administrated	 independently	 through	 an	 intravenous	
infusion	 line	 or	 added	 to	 the	 parenteral	 nutrition	 bag	 as	 the	 standard	 amino	 acids	
formulas	and	“all-in-one”	parenteral	nutrition	bags	do	not	contain	free	glutamine.	
Sometimes,	 stock	 solutions	 are	made.	 In	 this	 case	 the	 glutamine	 solution	 should	 be	
frozen	in	small	aliquots	into	sterile	containers.	When	needed,	these	small	aliquots	can	
be	thawed	in	the	refrigerator	before	use.	
However,	this	process	is	time-consuming	and	adding	glutamine	to	a	parenteral	nutrition	
bag	increases	the	risk	of	contamination	and	errors	in	formulation.	These	limitations	in	
its	clinical	use	initiated	research	for	new	ways	of	glutamine	delivery17:	
• Dipeptides	are	the	most	frequently	used	alternative	source	of	glutamine	and	are	
stable	 and	 soluble	 in	 aqueous	 solutions.	 The	 synthetic	 glutamine-containing	
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dipeptides,	 alanyl-glutamine	 or	 glycyl-glutamine,	 are	 hydrolyzed	 rapidly	 after	
intravenous	administration,	being	an	adequate	source	of	free	glutamine.	Those	
dipeptides	 are	 stable	 during	 prolonged	 storage	 periods	 in	 aqueous	 solutions.	
Some	 well-balanced	 amino	 acid	 solutions	 contain	 alanyl-glutamine	 or	 glycyl-
glutamine	and	can	be	added	easily	to	any	parenteral	solutions	or	to	the	all-in-
one	multichamber	bag17.	
• Ornithine	alfa-ketoglutarate	is	a	salt	formed	of	two	molecules	of	ornithine	and	
one	molecule	of	alfa-ketoglutarate.	Ornithine	alfa-ketoglutarate	has	showed	to	
improve	 the	 protein	 status	 in	 patients	 with	 protein	 depletion	 by	 restoring	
glutamine	pools,	as	both	molecules	(ornithine	and	alfa-ketoglutarate)	increased	
glutamate	levels	and	so	can	be	considered	as	glutamine	precursors.	However,	
their	stability	and	solubility	are	still	poor18.	
• Branched-chain	 amino	 acids	 are	 essential	 amino	 acids	 that	 serve	 as	 essential	
substrates	and	regulators	 in	 the	synthesis	of	body	proteins	and	represent	the	
major	 nitrogen	 source	 for	 glutamine	 and	 alanine	 synthesis	 in	muscle.	 During	
critical	illness,	the	endogenous	use	of	branched-chain	amino	acids	for	glutamine	
synthesis	is	increased19.	
• N-acetyl-glutamine:	are	high	soluble	and	stable,	taken	up	rapidly	and	hydrolyzed	
by	acylases	after	their	parenteral	administration.	However,	they	are	poorly	used	
due	to	restricted	acylase	capacities.		
• Glutamate	is	maybe	the	most	direct	related	substance	with	glutamine	and	stable	
in	 water	 solutions.	 Nonetheless,	 glutamate	 is	 not	 used	 as	 it	 hardly	 passes	
through	cell	membranes	and	high	doses	can	cause	neurotoxic	side	effects.	
	
Figure	 4.	 Relation	 between	 glutamine	 production,	 branched-chain	 amino	 acids,	 alfa-
ketoglutarate	and	glutamate.	BCAA:	branched-chain	amino	acids.	BCKA:	branched-chain	keto	
acid.	 α-KG:	 alfa	 ketoglutarate.	 Glu:	 glutamate.	 Gln:	 glutamine.	 Ala:	 alanine.	 [Adapted	 from	
Holecek	et	al.19].	
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4	Glutamine	administration	
Glutamine	can	be	administrated	by	both	enteral	and	intravenous	route,	provided	alone	
or	 integrated	 in	 the	 artificial	 nutrition	 solution.	 Intolerance	 to	 enteral	 feeding	 is	 a	
common	finding	in	critically	ill	patients	and	the	glutamine	absorption	is	low	due	to	the	
strong	 first	 pass	 metabolism	 in	 the	 intestine;	 consequently,	 enteral	 glutamine	
supplementation	 is	 not	 so	 beneficial	 because	 most	 of	 the	 administrated	 glutamine	
doesn’t	reach	the	systemic	circulation.	In	fact,	enteral	glutamine	delivery	preferentially	
increases	glutamine	disposal	in	the	enterocytes	and	intestine	immune	cells8.		
When	 given	 intravenously,	 plasma	 glutamine	 concentration	 increases	 by	 70%	 by	
intravenous	 infusion	 of	 exogenous	 glutamine	 dipeptide20.	 In	 spite	 the	 fact	 that	
glutamine	 is	 able	 to	 normalize	 plasma	 glutamine	 concentration,	 glutamine	
supplementation	 does	 not	 attenuate	 depletion	 of	 muscle	 free	 glutamine	 neither	
increases	the	intracellular	storage20,21.	5	Guidelines	and	recommendations	
The	 European	 Society	 for	 Clinical	 Nutrition	 and	 Metabolism	 (ESPEN)	 is	 a	 scientific	
organization	 dedicated	 to	 all	 relevant	 issues	 in	 the	 field	 of	 clinical	 nutrition	 and	
metabolism	 and	 promotes	 the	 clinical	 research	 of	 parenteral	 and	 enteral	 nutrition	
support.	The	ESPEN	publishes	guidelines	and	position	papers	about	recommendations	
for	clinical	nutrition	practices	at	a	regular	basis.	
The	 ESPEN	 guideline	 on	 parenteral	 nutrition	 in	 the	 intensive	 care	 published	 in	 2009	
recommended	adding	0.2-0.4	g/kg/day	of	 intravenous	glutamine	(0.3-0.6	g/kg/day	of	
alanyl-glutamine	 dipeptide)	 when	 parenteral	 nutrition	 is	 indicated,	 which	 is	 given	 a	
grade	A	 of	 evidence.	When	 glutamine	 cannot	 be	 incorporated	within	 the	 parenteral	
nutrition	itself,	it	can	be	administered	through	an	intravenous	line22.	
The	American	Society	for	Parenteral	and	Enteral	Nutrition	(ASPEN)	published	a	position	
paper	 of	 parenteral	 nutrition	 glutamine	 supplementation	 in	 2011,	 giving	 strong	
evidence	that	parenteral	nutrition	glutamine	supplementation	has	beneficial	effects	in	
certain	patient	population,	including	the	critically	ill	patients,	and	has	not	shown	to	be	
harmful	although	it	should	be	used	in	caution	in	patients	with	hepatic	and	renal	failure23.	
However,	 past	 2016,	 the	 ASPEN	 published	 new	 guidelines	 for	 the	 provision	 and	
assessment	 of	 nutrition	 support	 therapy	 in	 the	 adult	 critically	 ill	 patient	where	 they	
recommended	 with	 moderate	 evidence	 based	 on	 the	 newer	 reported	 results	 of	
randomized	 trials	 that	 parenteral	 glutamine	 supplementation	 should	 not	 be	 used	
routinely	in	the	critical	care	setting24.		
The	 Canadian	 Clinical	 Practice	 Guidelines	 (CCPG)	 from	 2003	 of	 nutrition	 support	 in	
mechanically	 ventilated	 critically	 ill	 adult	 patients	 recommended	 parenteral	
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supplementation	 with	 glutamine	 but	 not	 intravenous	 glutamine	 supplementation	 in	
critically	ill	patients	receiving	enteral	nutrition	due	to	insufficient	data25.	The	updated	
guideline	 of	 2015,	 however,	 changes	 their	 setting	 to:	 “when	 parenteral	 nutrition	 is	
prescribed	 to	 critically	 ill	 patients,	 we	 recommend	 parenteral	 supplementation	with	
glutamine	NOT	be	used”.		
Evidence-based	guidelines	are	systematically	developed	statements	based	on	published	
clinical	 trials	 and	meta-analyses.	 The	 older	 ESPEN	 and	 CCPG	 recommend	 glutamine	
supplementation,	however	the	recent	ASPEN	and	CCPG	guidelines	do	not	support	this	
point	of	view.	This	transition	in	the	recommendations	of	glutamine	supplementation	in	
the	guidelines	suspects	that	new	findings	do	not	support	the	traditional	evidence.		6	Clinical	evidence	of	parenteral	glutamine	supplementation	
Glutamine	supplementation	has	been	evaluated	in	more	than	20	years	in	many	clinical	
trials	and	meta-analysis	to	determine	if	there	is	a	positive	impact	on	clinical	outcomes.	
As	low	plasma	glutamine	levels	were	found	in	critical	illness	and	were	associated	with	
poor	outcomes	and	glutamine	may	improves	the	immune	system	function,	it	seems	to	
be	 logical	 that	 critically	 ill	 patients	 should	 obtain	 some	 benefit	 on	 exogenous	
replacement.	
Many	 of	 the	 early	 studies	 demonstrated	 significant	 improvement	 on	 outcomes,	
including	lower	mortality	rates,	reduction	in	infection	rates	and	less	hospital	length	of	
stay	 when	 total	 parenteral	 nutrition	 was	 supplied	 with	 glutamine.	 However,	 more	
recently	studies	failed	to	demonstrate	such	benefit,	 including	the	RDOX	trial	of	2013,	
currently	the	greatest	study	in	evaluating	glutamine	supplementation	efficacy6.	6.1	Pre-REDOX	studies	
Small	clinical	trials	were	performed	since	early	90s	in	order	to	discover	possible	benefits	
of	 glutamine	 supplementation	with	 parenteral	 nutrition.	 These	 studies,	 due	 to	 their	
similar	study	protocol,	can	be	considered	as	“traditional	glutamine	trials”.		
For	example,	in	2001,	Wischemeyer	et	al.26	conducted	a	randomized	trial	of	glutamine	
supplementation	 in	 twenty-six	 burn	 patients	 and	 concluded	 a	 significant	 fewer	
incidence	of	bacteremia	in	the	glutamine	supplemented	group.	In	addition,	decreased	
inflammation	and	a	trend	towards	lower	mortality	were	found.	
In	2006	Dechelotte	et	al.27	demonstrated	a	reduction	of	infectious	complications	and	a	
better	metabolic	tolerance	in	glutamine	supplemented	total	parenteral	nutrition	in	one-
hundred	fourteen	ICU	patients	in	16	different	hospitals	in	France.	
Other	 similar	 studies	 realized	 during	 this	 period	 found	 different	 beneficial	 results	
including	reduction	of	hospital	mortality28	and	six-month	mortality29,	serum	heat	shock	
protein	increasing	and	significant	decreased	ICU	length	of	stay30.		
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Larger	clinical	trials	were	performed	in	order	to	consolidate	the	results	that	were	found	
until	then,	as	most	realized	studies	were	too	small	to	detect	significant	differences	in	
mortality	or	infectious	complications	and	could	mostly	just	concluded	a	trend	towards	
better	 outcomes.	 However,	 against	 their	 study	 hypothesis,	 these	 newer	 and	 more	
scientific	strength	studies	did	not	confirm	previous	conclusions.	
The	Scottish	Intensive	care	Glutamine	or	seleNium	Evaluative	Trial	(SIGNET)31	and	the	
Scandinavian	glutamine	trial32,	two	large	multi-center	well-conduced	trials,	published	in	
2011,	found	a	lack	of	benefit	in	glutamine	supplementation	with	parenteral	nutrition.	
Where	the	Scandinavian	study	observed	a	reduced	ICU	mortality,	although	not	in	the	6-
month	 mortality	 and	 sequential	 organ	 failure	 assessment	 (SOFA),	 the	 SIGNET	 trial	
showed	neither	statistical	significance	on	the	ICU	and	6-month	term	mortality	nor	new	
infection	rates	between	the	supplemented	group	and	the	control	group.	However,	the	
SIGNET	study	used	low	doses	of	glutamine	(mean	of	20.2	g/day).	
These	new	findings	paid	attention	to	some	clinical	researchers	and	were	consequently	
examined	 in	 different	meta-analysis	 to	 determine	 a	more	 precise	 estimation	 of	 the	
effects	of	glutamine	treatment	on	patients’	outcomes.	
Bollhalder	et	al.33	included	forty	randomized	clinical	trials	(RCT)	that	were	published	in	
the	period	between	1990	and	2012.	 The	 results	 concluded	a	 significant	 reduction	of	
infectious	complications,	a	shortening	in	hospital	LOS	but	no	significant	reduction	of	the	
short-term	and	6-month	mortality.	Although,	when	they	considered	only	doses	above	
0.2	 g/kg/day	with	 a	 duration	of	more	 than	nine	days	 of	 glutamine	 administration,	 a	
significant	reduction	of	short	term	mortality,	infections	and	hospital	length	of	stay	were	
found,	concluding	 that	glutamine	dose	and	duration	of	administration	 influences	 the	
clinical	 outcomes	 of	 the	 patients.	 However,	 the	 exclusion	 of	 the	 SIGNET	 trial	 in	 the	
analysis	improves	all	outcomes.	
The	meta-analysis	of	Wischemeyer	et	al.34	was	conducted	after	the	launch	of	the	REDOX	
trial	in	order	to	contrast	new	findings	with	prior	results	by	focusing	only	on	the	previous	
published	articles.	Twenty-six	traditional	glutamine	trials	were	finally	included.	The	main	
finding	was	a	significant	reduction	in	hospital	mortality.	Secondary	outcomes	showed	
significant	 reductions	 of	 hospital	 length	 of	 stay	 and	 trends	 towards	 reduction	 in	
infectious	complications	and	ICU	length	of	stay	with	a	more	significant	signal	in	higher	
quality	studies	than	lower	quality	trials.		6.2	The	REDOX	trial	
A	totally	different	and	new	regimen	of	glutamine	supplementation	was	tested	in	this,	
until	 now,	 largest	 multicenter	 randomized	 clinical	 trial	 in	 evaluating	 the	 efficacy	 of	
glutamine6.	 Glutamine	 was	 considered	 a	 pharmaconutrient	 and	 administrated	
separately	from	the	standard	nutrition	support,	which	could	be	enteral	or	parenteral.	
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The	 field	 of	 pharmaconutrition	 can	 be	 understood	 as	 using	 nutrients	 in	 a	
pharmacological	way	and	not	simply	for	restoring	nutrient	deficiency.		
In	total,	1223	critically	 ill	patients	around	the	world	which	present	multiorgan	failure	
and	received	mechanical	ventilation	were	 included	 in	 this	 study.	Glutamine,	given	as	
dipeptide	alanyl-glutamine	in	pharmacological	doses	in	combination	with	intravenous	
and	enteral	supplements,	was	provided	together	with	antioxidants	and	administration	
was	started	within	24	hours	after	admission	to	the	ICU.		
The	 results	 found	were	 in	 contradiction	with	 the	 initial	 propounded	hypothesis.	 The	
group	receiving	glutamine	supplementation	shows	a	trend	towards	an	increased	28-day	
mortality	 and	 significant	 higher	 hospital	 mortality	 and	 6-month	 mortality.	 On	 side,	
glutamine	had	no	beneficial	effect	on	rates	of	organ	failure	or	infectious	complications.		
The	REDOX	trial	was	followed	by	a	post-hoc	analysis	published	by	the	same	authors35.	
The	 aim	 of	 this	 study	 was	 to	 evaluate	 the	 effect	 of	 glutamine	 supplementation	 in	
different	subgroups	of	baseline	characteristics.		
The	28-day	mortality,	the	primary	outcome	of	the	study,	was	only	significantly	increased	
in	 patients	who	 presented	 renal	 failure	 at	 baseline.	 Glutamine	 intervention	was	 not	
associated	with	 harm	 or	 benefit	 in	 patients	without	 baseline	 renal	 dysfunction.	 The	
harm	 caused	 of	 glutamine	 supplementation	 in	 patients	 with	 renal	 impairment	 was	
attenuated	in	the	presence	of	dialysis,	with	could	help	in	preventing	the	accumulation	
of	glutamine	or	other	harmful	metabolites	derivate	from	glutamine.				
In	 conclusion,	 the	 authors	 of	 the	 REDOX	 trial	 recommended	 to	 be	 cautious	 when	
providing	high-dose	glutamine	supplementation	to	critically	ill	patients	with	multiorgan	
failure,	 particularly	 to	 patients	 with	 renal	 failure	 but	 their	 results	 should	 not	 be	
generalized	to	the	rest	of	ICU	patients	who	can	have	some	benefit	in	lower	doses.	6.3	Understanding	the	REDOX	trial	
The	 findings	 of	 the	 REDOX	 trial	 were	 not	 as	 expected	 and	 differed	 from	 previous	
findings.	However,	these	new	results	cannot	be	ignored	due	to	its	scientific	strength	and	
high-quality	design,	being	prospective	enveloped,	randomized,	double	blind	controlled	
and	carefully	performed	and	executed	among	a	large	number	of	patients	from	different	
major	centers	in	North	America	and	Europe.		
The	REDOX	 trial	 is	 based	on	 a	 completely	 new	way	of	 glutamine	utilization	 as	 some	
points	of	their	study	protocol	differed	most	of	the	previous	studies	which	could	have	
promoted	the	discrepancies	in	results	found	between	them:		
• A	 combination	 of	 glutamine	 supplementation	 by	 enteral	 and	 intravenous	
pathway	 was	 used	 and	 glutamine	 was	 administrated	 separately	 from	 the	
artificial	nutrition	support.	As	it	was	suggested	that	enteral	supplementation	has	
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beneficial	effects	on	splanchnic	tissues	and	intravenous	supplementation	on	the	
overall	tissues,	it	seems	rational	that	co-administration	would	be	more	beneficial	
on	the	patient’s	health.	However,	this	regimen	was	never	used	before	and	could	
lead	to	an	excessive	glutamine	delivery.		
• Glutamine	was	administrated	in	high	doses,	arriving	up	to	0.6-0.8	g/kg/day.	This	
supraphysiologic	 dose,	 understood	 as	 delivering	 glutamine	 in	 amounts	 that	
exceed	the	naturally	glutamine	production	of	the	body,	was	 justified	with	the	
underlying	 idea	 of	 glutamine	 being	 a	 pharmaconutrient	 or	 immunonutrient	
rather	than	just	a	part	of	the	nutrition	support.	Nonetheless,	this	dosage	can	lead	
to	unknown	adverse	effects	and	have	a	negative	impact	on	the	patient’s	health.		
• Glutamine	 treatment	 started	 within	 24	 hours	 after	 the	 ICU	 admission	
corresponding	to	the	acute	phase	of	critical	illness.	The	intention	was	preventing	
the	development	of	glutamine	deficiency.	 In	contrast,	 in	 the	 traditional	 trials,	
glutamine	was	administrated	when	parenteral	nutrition	was	required,	mostly	in	
later	phases	of	 ICU	stay.	Nutrition,	stress	and	metabolic	states	of	the	patients	
vary	during	the	different	phases	of	the	illness	process	and	could	have	influenced	
the	response	to	glutamine.		
• Glutamine	was	mixed	with	other	antioxidants	as	both	seem	to	potentiate	the	
defense	system	and	benefit	the	critically	 ill	patients.	The	combination	of	both	
treatments,	 however,	 confuse	 as	 findings	 can	 be	 caused	 by	 glutamine,	
antioxidants	or	by	the	interaction	of	supplying	both	together	(e.g.	glutamine’s	
positive	effects	could	have	been	blocked	or	countered	by	antioxidants).		
• Only	 patients	 with	 at	 least	 two	 organ	 failures	 were	 included	 in	 their	 study	
without	exclusion	of	renal	and	liver	failure.	Heyland	et	al.	suggested	that	patients	
with	organ	dysfunction	would	most	likely	have	low	plasma	glutamine	levels	and	
therefore	would	benefit	the	most	from	supplementation.	However,	kidneys	and	
liver	are	central	organs	in	glutamine	metabolism	and	consequently	impairment	
of	one	or	both	organs	could	increase	the	glutamine	and	ammonia	blood	levels	
above	the	physiological	upper	limit	and	being	toxic.	
• On	average,	the	amount	of	energy	and	proteins	administrated	to	the	patients	
was	less	than	50%	of	patients’	needs	and	so	quite	insufficient.	Patients	may	not	
benefit	 from	 glutamine	 supplementation	 when	 they	 are	 underfed	 because	
inadequate	 clinical	 nutrition	 significantly	 affects	 the	 outcomes	 in	 case	 of	 ICU	
patients.	
• Most	of	 the	 included	patients	below	to	medical	 ICU	wards	 though	most	 trials	
have	demonstrated	that	surgical	and	oncological	ICU	patients	may	benefit	most	
from	glutamine	supplementation.		
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Considering	these	points,	the	differences	between	traditional	glutamine	trials	and	the	
REDOX	trial	can	be	resumed	as	shown	in	Table	16,34:	
Table	 1.	 Principal	 differences	 between	 traditional	 glutamine	 supplementation	 trials	 and	 the	
REDOX	trial.	
	 Traditional	glutamine	trials	 The	REDOX	trial	 	 	
Study	design	 Small	trials	 Large	multicenter	trial	
Artificial	 nutrition	
administration	
Patients	 mostly	 requiring	
parenteral	nutrition	
Patients	 with	 enteral	 or	
parenteral	nutrition	regimens	
Glutamines’	role	 Supplement	 of	 the	 artificial	
nutrition	support	
Pharmaconutrient		
Glutamine	
administration		
Mixed	 together	 with	 artificial	
nutrition	 support	 (mostly	
parenteral)	
Separate	 from	 the	 nutrition	
support	 through	 both	 enteral	
and	parenteral	route	
Start	 of	 glutamine	
administration	
Later	 in	 the	 course	 of	 ICU	
admission	
Within	 24	 hours	 of	 ICU	
admission	
Glutamine	dosage	 Physiological	doses		 Supraphysiological	doses		
Patient	type	 Mostly	surgical	 Mostly	medical	
Patients	with	renal	or	
liver	failure	
Excluded	 Included	
6.4	Post-REDOX	studies	
After	publishing	the	results	of	the	REDOX	trial,	new	meta-analyses	were	performed	in	a	
need	 to	 update	 the	 evidence	 of	 glutamine	 supplementation	 in	 critically	 ill	 patients.	
These	new	meta-analyses	 included	and	analyzed	together	 traditional	glutamine	trials	
and	the	REDOX	trial.	
Chen	et	al.36	included	eighteen	randomized	clinical	trials.	The	primary	outcome,	hospital	
mortality,	was	not	significantly	different	between	the	glutamine	intervention	and	the	
control	group.	In	contrast,	the	incidence	of	nosocomial	infections	in	the	glutamine	group	
was	significantly	 lower	than	 in	the	control	group.	No	shortening	was	observed	 in	the	
hospital	length	of	stay	in	the	glutamine	supplemented	group.		
Sub-group	meta-analyses	were	 performed	 simultaneously	 to	 estimate	 the	 effects	 of	
glutamine	in	specific	patient	populations,	the	effects	related	to	a	specific	dosage	and	
the	 effects	 related	 to	 the	 nutritional	 supplementation	 method.	 Glutamine	 effects	
differed	 by	 ICU	 setting,	 where	 patients	 from	 surgical	 ICU	 wards	 most	 benefit	 from	
glutamine	supplementation	by	an	observed	reduction	of	nosocomial	infection	rate	and	
a	tendency	towards	decreased	mortality,	in	contrast	to	patients	from	medical	or	mixed	
ICU	wards.	Benefits	of	glutamine	were	found	in	patients	to	whom	parenteral	nutrition	
was	supplemented	with	glutamine,	but	not	were	glutamine	was	administrated	enterally.	
The	 high	 dose	 subgroup	 (above	 the	 0.5	 g/kg/day),	 as	 used	 in	 the	 REDOX	 trial,	were	
associated	with	an	increased	mortality	risk	in	ICU	patients.	
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The	Cochrane	database	review	of	Tao	et	al.37	found	moderate	evidence	that	glutamine	
supplementation	reduces	the	infection	rate	and	days	of	mechanical	ventilation	and	low	
evidence	that	glutamine	supplementation	reduces	the	length	of	hospital	stay.	Besides,	
glutamine	showed	no	or	very	little	effect	on	mortality	and	ICU	length	of	stay.		
The	meta-analysis	of	Oldani	et	al.38	of	 thirty	randomized	clinical	 trials	suggested	that	
glutamine	supplementation	given	to	critically	ill	patients	does	not	significantly	reduce	
hospital	and	ICU	mortality.	Furthermore,	they	could	not	demonstrate	a	protective	effect	
of	 glutamine	 on	 infection	 rates.	 In	 their	 subgroup	 analysis,	 they	 could	 observe	 a	
protective	 roll	 of	 glutamine	 administrated	 intravenously	 for	 more	 than	 five	 days	 in	
patients	with	a	low	Acute	Physiology	and	Chronic	Health	disease	Classification	System	II	
(APACHE)	score	below	15.	
The	 differences	 in	 findings	 between	 the	 pre-REDOX	 and	 post-REDOX	 realized	meta-
analyses	were	mostly	due	to	the	inclusion	of	results	of	the	REDOX	trial.	All	three	meta-
analyses	 suggest	a	need	 for	new	 large	clinical	 trials	 to	confirm	or	deny	 the	potential	
protective	or	harmful	effects	of	glutamine	in	more	specific	subgroups	of	patients.		
Only	few	new	clinical	trials	have	been	published	since	the	REDOX	trial	in	a	try	to	answer	
the	new	questions	raised	and	to	fill	the	gap	of	the	lack	of	good	clinical	evidence	in	the	
use	of	glutamine	supplementation	in	critically	ill	patients.		
Perez-Barcena	et	al.39	used	an	intravenous	glutamine	supplementation	(0.35	g/kg/day)	
to	 trauma	 patients	 with	 enteral	 or	 parenteral	 nutrition	 support.	 No	 evidence	 of	
glutamine	efficacy	could	be	found	in	any	measured	outcome	(new	infections,	length	of	
stay	and	mortality).	
Some	interesting	point	of	this	study	was	the	monetarization	of	glutamine	blood	levels.	
60%	 presented	 low	 baseline	 glutamine	 which	 significant	 increase	 in	 the	 glutamine	
supplementation	group	compared	to	the	non-glutamine	supplementation	group	after	
six	 days	 of	 treatment.	 Nevertheless,	 glutamine	 supplementation	 within	 the	
recommended	 guidelines	 dose	 was	 insufficient	 to	 normalize	 the	 levels	 of	 plasma	
glutamine	 in	 many	 patients	 which	 could	 explain	 the	 lack	 of	 effect	 in	 glutamine	
administration.	 Maintained	 low	 glutamine	 levels	 on	 day	 six	 was	 associated	 with	 an	
increased	number	of	infected	patients	and	a	longer	hospital	length	of	stay.		
In	the	randomized	clinical	trial	of	Grintescu	and	al.40,	glutamine	efficacy	was	measured	
by	the	incidence	of	hyperglycemic	episodes	and	insulin	consumption	as	poor	glycemic	
control	and	insulin	resistance	have	been	paired	with	complications	and	mortality.	They	
report	beneficial	effects	on	parenteral	nutrition	supplemented	with	glutamine	in	trauma	
patients.	
The	 most	 important	 trial	 published	 since	 the	 REDOX	 trial,	 the	 Glutamine	 Dipeptid	
(GLND)	trial	of	Ziegler	et	al.41,	demonstrated	that	glutamine	supplemented	parenteral	
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nutrition	is	safe	on	0.35	g/kg/day	(0.5	g/kg/day	of	alanyl-glutamine	dipeptide)	but	they	
could	not	demonstrate	any	improvement	in	clinical	outcomes	in	surgical	ICU	patients.	
At	time,	low	glutamine	plasma	levels	were	not	correlated	with	hospital	mortality.		6.5	The	ESPEN	meta-analysis	
Last	February	2017,	the	ESPEN	study	group	published	the	currently	most	recent	meta-
analysis	of	glutamine	supplementation.	In	this	new	study,	they	included	15	randomized	
clinical	 trials	which	 all	 strictly	 delivered	 glutamine	 supplementation	 according	 to	 the	
current	 clinical	 ESPEN	 guidelines:	 critically	 ill	 patients	 without	 hepatic	 and/or	 renal	
failure,	hemodynamically	 and	metabolically	 stablished	were	administrated	glutamine	
dipeptides	 via	 parenteral	 route	 at	 0.3-0.5	 g/kg/day	 in	 combination	 with	 adequate	
nutrition	for	at	least	3	days.		
In	contrast	to	other	meta-analysis	published	after	the	REDOX	trial,	this	particular	study	
using	precise	and	specific	inclusions	criteria	and	excluding	the	REDOX	trial,	proved	that	
glutamine	administration	according	 to	 the	2009	ESPEN	guidelines22	 reduces	 infection	
complications,	the	ICU	and	hospital	 length	of	stay,	the	number	of	days	of	mechanical	
ventilation	and	hospital	mortality	rate.		7	The	role	of	glutamine	in	the	ICU	
Positive	 evidence	 in	 support	 of	 intravenous	 glutamine	 supplementation	 comes	 from	
small	single-center	trials	which	are	individually	inconclusive.	These	traditional	glutamine	
trials	 include	small	sample	sizes	of	population	and	are	so	exposed	to	the	small	study	
bias.	 A	 reduced	 study	 population	 can	 make	 findings	 insensitive	 to	 possible	 harmful	
effects	that	can	be	identified	in	larger	trials.	Consequently,	these	small	trials	combined	
in	meta-analysis	are	not	able	to	detect	those	negative	effects.		
On	side,	most	of	this	meta-analysis	included	a	broad	range	of	different	studies	leading	
to	 design	 weakness	 and	 many	 potential	 confounder	 factors	 as	 different	 patient	
population,	different	administration	route	and	glutamine	form,	etc.	The	ESPEN	meta-
analysis,	although	using	more	accurate	inclusion	criteria	and	therefore	less	exposed	to	
a	bias	due	to	differences	in	the	way	of	glutamine	supplementation,	is	still	based	on	small	
studies	so	the	individual	statistical	power	can	be	questioned.		
Newer	and	 larger	multi-center	 trials	with	more	scientific	power	couldn’t	 support	 the	
same	beneficial	findings,	starting	by	the	SIGNET	and	Scandinavian	trials.	The	REDOX	trial	
was	the	first	in	suggesting	harmful	effects	to	glutamine	supplementation,	however	this	
trial	has	to	be	interpreted	with	caution	due	to	its	alternative	study	design.		
Several	 causes	 are	 suggested	 as	 related	 to	 the	 distinctive	 results	 reported	 in	 the	
performed	trials,	based	on	characteristics	of	the	different	patients	included	and	to	the	
regimen	of	glutamine	administration	used.	The	most	relevant	items	are	shown	in	Table	
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2.	Nevertheless,	more	aspects	can	be	 implicated	and	must	be	further	 investigated	to	
extract	final	conclusions	of	glutamine	supplementation.	
Table	 2.	 Patient	 characteristics	 and	 regimen	 of	 glutamine	 utilization	 related	 to	 different	
treatments.	
	
	
Probably	potentiate	beneficial	
treatment	effects	
Probably	 contribute	 to	
insignificant	 or	 prejudicial	
treatment	effects	
Baseline	glutamine	level	 Low	 High	
Patient	type	 Surgical	and	oncological	 Medical	
Organ	dysfunctions	 No	 renal	 and/or	 liver	
impairment	
Renal	and/or	liver	impairment	
Administration	route	 Intravenous	 Enteral	
Dose	 Physiological		 Supraphysiological		7.1	Patient	characteristic	
Not	all	critically	 ill	patients	are	at	 the	same	degree	of	 illness.	The	baseline	condition,	
adaptive	response	and	stress	 levels	 influence	the	final	response	to	glutamine.	Not	all	
patients	may	experience	the	same	advantage	of	exogenous	glutamine	administration.	
Glutamine	supplementation	could	not	be	sufficient	to	improve	health	and	support	the	
recovery	in	those	most	severe	ill	as	its	protective	role	may	is	not	significant	to	attenuate	
damage	caused	by	the	underlying	disease.	Meanwhile,	sicker	patients	could	be	earlier	
suffering	from	the	toxicity	effects	of	glutamine.		
Besides,	positive	effects	of	glutamine	are	found	in	trials	where	patients	with	renal	or	
liver	 impairment	 are	 excluded.	 Patients	 with	 baseline	 renal	 impairment	 were	
significantly	associated	with	an	increased	risk	for	mortality	in	the	REDOX	trial	which	was	
not	observed	in	the	normal	renal	function	subgroup.	However,	not	all	types	of	organ	
failure	would	have	the	same	effect	on	glutamine	supplementation	as	kidney	and	liver	
are	those	implied	in	its	metabolism.		
Surgical	and	medical	patients	have	also	shown	to	react	on	a	distinct	way	to	glutamine.	
Surgical	 ICU	 patients,	 including	 burns	 injury	 and	 trauma	 patients,	 are	more	 likely	 to	
benefit	 from	 glutamine.	 It	 has	 been	 suggested	 that	 surgical	 patients	 may	 be	 more	
susceptible	to	glutamine	depletion	due	to	higher	stress	levels,	mechanical	obstruction,	
cachexia	or	blood	loss	or	limitation	of	food	intake	and	absorption	as	their	intestine	track	
may	be	impaired.	Oncology	patients	are	also	hypothesized	to	have	a	greater	chance	of	
benefit	from	glutamine	treatment	as	tumors	are	great	consumers	of	glutamine.				
Maybe	the	most	impacting	finding	is	that	critical	illness	is	not	necessarily	associated	with	
low	 baseline	 glutamine	 levels.	 Several	 newer	 studies	 started	 to	 record	 glutamine	
baseline	 levels	 but	 could	 only	 confirm	 glutamine	 deficiency	 in	 part	 of	 the	 study	
population.	 Low	 baseline	 glutamine	 levels	 have	 been	 associated	 as	 an	 independent	
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predictive	risk	factor	for	mortality	and	mobility	but	this	fact	is	not	so	consistent,	as	it	
could	 not	 be	 concluded	 in	 all	 trials.	 Curiously,	 some	 critically	 ill	 patients	 present	
remarkably	elevated	baseline	levels,	above	the	physiological	upper	limit	maybe	due	to	
the	increased	muscle	release	or	decreased	liver	uptake	and	metabolism.	High	baseline	
glutamine	 has	 also	 been	 found	 to	 be	 a	 risk	 factor	 for	 mortality.	 Glutamine	
supplementation	 in	 patients	 with	 high	 baseline	 glutamine	 levels	 would	 probably	
potentiate	 toxicity	 and	 lead	 to	 worse	 outcomes.	 Figure	 5	 present	 a	 simulation	 of	
additional	prediction	of	mortality	when	glutamine	plasma	concentration	at	admittance	
to	ICU	is	outside	the	physiological	range.		
	
Figure	5.	Simulation	of	the	additional	prediction	of	mortality	rate	from	an	out	of	range	glutamine	
concentration	 at	 admittance.	 The	 black	 line	 is	 the	 APACHE-predicted	 rate	 if	 the	 plasma	
glutamine	concentration	at	admittance	is	within	the	range	400-930	µmol/l.	With	an	admittance	
concentration	outside	of	that	range,	the	dotted	curve	represents	the	predicted	mortality	rate,	
suggesting	a	mortality	rate	of	50%	at	APACHE	20	in	contrast	with	APACHE	29.5	if	the	glutamine	
concentration	is	not	considered.	[Adapted	from	Rodas	et	al.14].	7.2	Regimen	of	glutamine	utilization	
High	doses	of	any	substance	can	lead	to	toxic	effects	and	in	contrast	low	doses	can	be	
insignificant	to	produce	positive	effects	on	the	patient’s	health.	The	trick	is	finding	the	
adequate	dose	 to	 improve	 the	patient’s	 outcomes	without	 being	 harmful.	Nearly	 all	
positive	glutamine	studies	used	physiological	doses	of	glutamine	within	 the	different	
guidelines	recommendations	and	have	not	been	paired	to	any	harmful	effect.	However,	
high	glutamine	doses	regarding	to	the	immunonutrition	concept	result	in	poor	clinical	
outcomes.	The	glutamine	toxicity	mechanism	is	still	unknown	but	too	high	glutamine	
doses	may	result	in	metabolic	imbalances.		
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Administrated	glutamine	doses	must	be	able	to	normalize	plasma	glutamine	as	this	is	
the	 suggested	mechanism	whereby	 glutamine	 can	 support	 the	 immune	 system	 and	
normalize	cell	function.	Only	few	studies	have	determined	glutamine	levels	at	baseline	
and	after	some	days	of	glutamine	treatment.	These	could	 find	significant	differences	
between	the	intervention	and	control	group	in	restoring	plasma	glutamine	levels	with	
physiological	dose.	But	 it’s	not	 clear	 if	 this	 is	enough	 to	normalize	glutamine	 related	
physiological	 functions	 and	 to	 improve	 the	 immune	 system.	 Besides,	 depletion	 of	
intracellular	muscle	glutamine	is	not	attenuated	by	an	exogenous	glutamine	infusion.		
The	 used	 route	 of	 glutamine	 administration	 affects	 the	 subsequent	 plasma	
concentration	and	consequently	the	response	to	supplementation.	In	this	bibliographic	
review,	intravenous	glutamine	administration	was	analyzed	as	this	is	the	most	evidence-
based	route.	Positive	effects	on	enteral	glutamine	administration	have	never	been	as	
consistent	 as	 parenteral	 administration	 and	 do	 not	 increase	 that	 much	 the	 plasma	
levels.	 The	 recent	 published	MetaPlus	 trial43	 didn’t	 help	 to	 firm	 benefits	 of	 enteral	
administration	 as	 the	 intervention	 group,	 fed	 with	 enriched	 enteral	 nutrition	 with	
immune-modulating	 nutrients	 (including	 glutamine,	 antioxidants	 and	 fish	 oils)	 was	
associated	with	a	higher	six-month	mortality	without	any	improvement	in	other	studied	
endpoints	(such	as	infection	complications).		
Glutamine	supplementation	with	parenteral	nutrition	is	mostly	started	after	some	days	
of	 ICU	 admission,	 as	 parenteral	 nutrition	 is	 not	 the	 first	 chosen	 option	 to	 cover	
nutritional	 requirements	 in	 the	 critically	 ill	 patients.	 Pharmacological	 glutamine	
administration	is	designed	to	be	started	at	admission	to	the	ICU,	without	taking	account	
if	 the	 patient	 receives	 enteral	 or	 parenteral	 nutrition.	 Patient’s	 state	 and	 degree	 of	
illness	differ	 in	 early	 and	 later	phases	of	 ICU	 stay	 and	 so	 the	 glutamine	efficacy	 and	
toxicity	 can	 vary	 between	 “early”	 and	 “late”	 start	 of	 supplementation.	 Onside,	 by	
choosing	only	patients	needing	parenteral	nutrition	support,	a	subgroup	of	critically	ill	
patients	 could	 be	 selected	 to	 whom	 glutamine	 is	 especially	 beneficial	 (e.g.	 their	
gastrointestinal	tract	is	more	impaired	leading	to	less	proper	defense	support	which	is	
improved	by	exogenous	glutamine	delivery).			
Early	studies	have	used	l-glutamine	and	later	studies	glutamine	dipeptide	compositions	
due	to	their	better	stability.	It’s	not	clear	if	and	how	this	could	influence	the	results	of	
the	glutamine	treatment,	however	differences	between	these	different	sources	in	their	
kinetics	and	final	release	of	free	glutamine	in	plasma	are	observed.	8	An	alternative	point	of	view	
Trials	 are	 performed	 on	 the	 hypothesis	 that	 apparent	 glutamine	 deficiency	
compromises	 an	 adequate	 immune	 system	 function	 and	 cell	 survival	 and	 therefore	
glutamine	 supplementation	 should	 improve	 the	 outcome	 in	 severely	 ill	 patients.	
Nevertheless,	this	suggesting	could	be	erroneous	and	low	glutamine	levels	during	acute	
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critical	illness	could	reflect	just	an	adaptive	and	beneficial	stress	response	rather	than	a	
conditional	deficiency.	Administration	of	exogenous	glutamine	could	 interfere	 in	 this	
favorable	response	and	so	worsen	outcomes.		
Maybe	glutamine	plays	a	role	in	several	prior	mentioned	physiological	functions	and	its	
depletion	 is	 a	 marker	 of	 disease	 severity	 but	 exogenous	 supplementation	 and	
enhancement	 of	 plasma	 levels	 is	 not	 determinant	 to	 improve	 outcomes.	 Maybe	
decreased	 glutamine	 levels	 just	 reflect	 the	 typical	 global	 protein	 depletion	 without	
having	any	essential	function	for	critically	ill	patients.		
In	 these	 cases,	 the	 significant	 differences	 between	 the	 control	 and	 the	 intervention	
groups	that	were	found	in	some	trials	could	be	caused	by	an	unknown	or	undetermined	
study	bias.		9	Further	research	
With	all	the	available	information,	it’s	still	uncertain	if	glutamine	should	be	included	in	
the	routine	clinical	use.	New	trials	have	only	lead	to	more	confusion	and	current	clinical	
evidence	 interpretation	 vary	widely	 between	 different	 authors.	 The	 REDOX	 trial	 has	
mostly	contributed	 to	question	 the	scientific	 recommendations	published	until	2013.	
Currently,	 glutamine’s	 use	 according	 to	 the	 ESPEN	 guidelines	 seems	 to	 be	 the	most	
effective	and	safe	way	of	glutamine	delivery.		
In	 this	 same	 line,	 optimal	 nutrition	 support	 for	 critically	 ill	 patients	 remains	
controversial.	 It’s	 difficult	 to	 predict	 energy	 expenditure	 and	 protein	 needs	 in	 those	
patients	 due	 to	 the	 complex	 and	 variable	 metabolic	 alterations	 suffered.	 Artificial	
nutrition	support	and	intravenous	glutamine	supplementation	are	still	unphysiological	
ways	of	feeding	and	not	without	complications.	In	overall,	the	optimal	amount,	route	
and	 timing	 of	 artificial	 nutritional	 support	 and	 glutamine	 supplementation	 are	
uncertain.		
New	research	should	explain	if	glutamine	supplementation	is	harmful,	a	complete	waste	
and	insignificant	or	only	relevant	for	some	subgroups	of	patients.	And	so,	it’s	important	
to	 define	 safe	 and	 effective	 regimens	 of	 glutamine	 supplementation	 and	 the	 right	
specific	subgroups	of	patients	who	potentially	may	benefit	from	this	treatment.	The	next	
questions	 should	 be	 further	 investigated	 in	 order	 to	 propose	 new	 valid	
recommendations:	
• Which	patients	present	 low	baseline	glutamine	 levels,	 taking	 into	account	the	
underlying	disease,	illness	severity	and/or	nutritional	baseline	status?	
• How	 should	 glutamine	 supplementation	 be	 used	 in	 routine	 clinical	 practice	
(dosage,	days	of	treatment,	route	of	administration,	given	with	or	separately	of	
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nutrition	 support…)	 in	 order	 to	 restore	 glutamine	 plasma	 levels	 within	 the	
healthy	physiological	range?		
• Can	glutamine	supplementation	really	restore	low	glutamine	plasma	levels?		
• Can	restoration	of	the	plasma	glutamine	level	enhance	the	clinical	situation	of	
the	patient	and	so	improve	the	prognostic	and	the	clinical	outcomes?	
• Can	high	doses	of	glutamine	be	toxic?	Which	underlying	mechanism	is	implied	
and	how	should	it	be	avoid	or	treated?	
• Which	 subgroup	 of	 critically	 ill	 patients	 are	 at	 risk	 to	 show	 high	 glutamine	
baseline	levels	and	which	underlying	mechanism	is	implied?	
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Conclusions	
• Glutamine	is	an	important	amino	acid	for	the	human	body	in	health	and	disease,	
supporting	mostly	enterocytes	and	immune	system	cells.		
• Glutamine	 can	be	 synthetized	endogenously,	 but	during	 illness,	when	plasma	
levels	can	become	low	and	muscle	depletion	is	observed,	it	needs	probably	to	be	
supplied	exogenously.	And	so,	gutamine	is	considered	a	conditionally	essential	
amino	acid.	
• Glutamine	has	difficult	chemical	characteristics,	such	as	low	aqueous	solubility	
and	 stability.	 New	 delivery	 sources,	 like	 glutamine	 containing	 dipeptides	
included	in	commercial	amino	acid	solutions,	are	currently	more	popular	and	are	
easy	ways	to	include	glutamine	supplementation	to	the	regular	use.	
• Traditional	 studies	 associate	 glutamine	 supplementation	 with	 beneficial	
treatment	 effects,	 however	 newer	 and	 more	 scientific	 robust	 trials,	 as	 the	
REDOX	 trial,	 found	 contradictory	 results,	 questioning	 glutamine	
supplementation	 efficacy.	 Consequently,	 some	 big	 and	 important	 guidelines	
have	changed	their	recommendations.	
• Some	 patients’	 characteristics	 and	 glutamine	 regimen	 aspects	 promote	
beneficial	 treatment	 effects	 of	 glutamine	 while	 other	 aspects	 show	 more	
prejudicial	 effects.	 New	 trials	 should	 further	 investigate	 how	 these	 different	
points	influence	the	glutamine	efficacy.			
• Not	 all	 critically	 ill	 patients	 have	 low	 baseline	 glutamine	 and	 some	 have	
conversely	an	increased	plasma	level,	being	both	an	independent	predictor	of	
mortality.	Correcting	the	deficient	state	seems	to	be	logically	a	better	target	than	
over	 supplementing	non-deficient	 patients.	 Therefore,	 determining	 glutamine	
baseline	 levels	 and	 identifying	 patients	 with	 glutamine	 deficiency	 should	 be	
indispensable	before	any	glutamine	supplementation.	
• Besides,	it	is	still	unclear	if	the	depletion	in	glutamine	levels	contributes	to	death	
or	is	a	simple	marker	of	disease	severity	and	if	glutamine	contributes	to	enhance	
clinical	outcomes.				
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